Anti-ADAM12 antibodies for the treatment of cancer

摘要

The present disclosure concerns monoclonal antibodies directed to the pro-domain of ADAM 12 and their use in the treatment of cancer.

主权项

1. An antibody capable of specifically binding an epitope within the prodomain of ADAM12 (SEQ ID NO: 2), said antibody selected from the group consisting of:
vii the monoclonal antibody produced by the hybridoma cell line 7B8 deposited under the Budapest Treaty with HPA Cultures collection (ECACC) under accession number 13082101; viii the monoclonal antibody produced by the hybridoma cell line 8F8 deposited under the Budapest Treaty with HPA Cultures collection (ECACC) under accession number 13082102; ix an antibody capable of binding the same epitope as 7B8 or 8F8; x an antibody capable of inhibiting binding of 7B8 or 8F8 to ADAM12; xi an antibody having the VH and VL of 7B8 or 8F8; xii an antibody having the CDRs of the VH and VL of 7B8 or 8F8.